Media

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

April 8, 2026

RenovoRx today announced that the Japan Patent Office (JPO) has issued a Notice of Allowance for the Company’s first Japanese patent application (JP 2024-559262) titled “Method and Apparatus for Delivering…

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

April 1, 2026

RenovoRx today announced that it has been named on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 as number 10 in the medical device category. This…

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

March 30, 2026

RenovoRx today announced its financial results for the full year and fourth quarter ended December 31, 2025, and is providing a business update to shareholders.

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

March 26, 2026

RenovoRx today announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion…

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

March 23, 2026

RenovoRx today announced the closing of its previously announced, oversubscribed private placement of common stock and revenue milestone warrants. The private placement resulted in gross proceeds of approximately $10 million…

RenovoRx Announces $10 Million at Market Private Placement

March 18, 2026

RenovoRx today announced the execution of definitive securities purchase agreements with institutional investors for an oversubscribed common stock and milestone warrant private placement which is expected to result in gross…

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

February 27, 2026

RenovoRx today announced continued commercial progress, with 12 U.S. cancer centers now utilizing the RenovoCath device. These 12 centers are in addition to those centers currently using RenovoCath as part…

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

February 26, 2026

RenovoRx today announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted.

RenovoRx Establishes RenovoCath® Medical Advisory Board

February 10, 2026

RenovoRx today announced the formation of a dedicated RenovoCath Medical Advisory Board (“MAB”) to support its clinical and strategic initiatives.

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

February 5, 2026

RenovoRx is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026.

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

February 4, 2026

RenovoRx today announced that new clinical data will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026. The clinical data abstract entitled,…

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

January 28, 2026

RenovoRx today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February 4–8, 2026 in Savannah, Georgia.

* Individual results may vary.

Mark Voll Joins RenovoRx as Chief Financial Officer

February 19, 2026

RenovoRx Inc. has welcomed a new member to its senior leadership team, hiring Mark Voll as chief financial officer (CFO), effective Feb. 1.

Why Commercial Discipline Starts Long Before Launch

February 17, 2026

Shaun Bagai is the CEO of RenovoRx, a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared local drug-delivery device, targeting high unmet medical needs.

Interview with Shaun Bagai: Revolutionary Cancer Treatment, Startup Success, & Medtech Mentorship

January 23, 2026

Shaun Bagai is the CEO and Director of RenovoRx, and a seasoned MedTech leader whose path began with a Silicon Valley startup internship that ultimately pulled him away from medical…

Nanoparticles and Beyond: Novel Drug Delivery Strategies for Cancer

January 13, 2026

A major breakthrough in cancer drug delivery took place in 1995, when the FDA approved the first nanodrug, Doxil—a liposomal formulation of doxorubicin engineered to preferentially accumulate in tumors. Since…

Revolutionizing Cancer Treatment: The Future of Localized Drug Delivery to Tumors with CEO Shaun Bagai

November 25, 2025

In this compelling episode of MedTech 101, host Rodney Moses sits down with RenovoRx CEO Shaun Bagai to explore the latest breakthroughs in cancer treatment. The conversation opens with a…

First Patient Treated in RenovoCath Clinical Trial

November 10, 2025

RenovoRx Inc.’s study of its U.S. Food and Drug Administration (FDA)-cleared drug delivery device, RenovoCath, has marked a major milestone with the first patient treatment at the University of Vermont Cancer…

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots

September 29, 2025

Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at SSO 2025.

From Trials to Hope: A New Approach to Treating Pancreatic Cancer

September 27, 2025

Shaun Bagai, CEO of RenovoRx, joined us to discuss an innovative approach delivering chemo directly to pancreatic tumors. By targeting the cancer more precisely, this treatment may reduce side effects…

RenovoRx Panther Study Progresses with First Clinical Procedure

September 26, 2025

RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont Cancer Center, and two additional sites—Baptist Health Miami Cancer Institute and…

How Skipping The CRO Helped RenovoRx Get Closer To Patients

September 24, 2025

In this Q&A, RenovoRx Chief Clinical Officer Leesa Gentry explains why they decided to forgo a CRO partner, discusses their in-house expertise, and shares how the decision helped them get…

PharmaShots Webinar: Mastering a Patient-Centric Approach for Treatment in Biopharma

August 29, 2025